{"id":475299,"date":"2020-03-20T16:18:02","date_gmt":"2020-03-20T16:18:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475299"},"modified":"2020-03-20T16:18:02","modified_gmt":"2020-03-20T16:18:02","slug":"autosomal-dominant-polycystic-kidney-disease-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/autosomal-dominant-polycystic-kidney-disease-market-insights-epidemiology-and-market-forecast-2030_475299.html","title":{"rendered":"Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast 2030"},"content":{"rendered":"
\"Autosomal<\/a><\/div>\n
DelveInsight’s ” Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

(Albany, NY) DelveInsight launched its new report on Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030<\/a>.<\/p>\n

DelveInsight’s ” Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Key facts of the report:<\/strong>
1. Autosomal Dominant Polycystic Kidney Disease affects more than 600,000 Americans and 12.4 million people worldwide.
2. Autosomal Dominant Polycystic Kidney Disease prevalence is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year.<\/p>\n

Key benefits of the report:<\/strong><\/p>\n

1. Autosomal Dominant Polycystic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Autosomal Dominant Polycystic Kidney Disease epidemiology and Autosomal Dominant Polycystic Kidney Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Autosomal Dominant Polycystic Kidney Disease market report provides insights on the current and emerging therapies.
3. Autosomal Dominant Polycystic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Autosomal Dominant Polycystic Kidney Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autosomal Dominant Polycystic Kidney Disease market.<\/p>\n

\"\"<\/p>\n

“Autosomal Dominant Polycystic Kidney Disease prevalence increased with age and reached a peak value of 261 per million population in the age group of 55-59 years in Japan.”<\/strong><\/p>\n

The key players in Autosomal Dominant Polycystic Kidney Disease market are:<\/strong>
1. Kyowa Hakko Kirin
2. Palladio Biosciences
3. Sanofi
4. Reata Pharmaceuticals
5. Regulus Therapeutics<\/p>\n

The launch of the emerging therapies is expected to significantly impact Autosomal Dominant Polycystic Kidney Disease treatment scenario in the upcoming years:-<\/strong><\/p>\n

Drugs covered:<\/strong>
1. Venglustat
2. Bardoxolone
3. Lixivaptan
4. RGLS4326<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction
2. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
3. Autosomal Dominant Polycystic Kidney Disease Background and Overview
4. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population
4.6. United States
4.7. EU-5
4.8. Assumptions and Rationale
4.9. Germany
4.10. France
4.11. Italy
4.12. Spain
4.13. United Kingdom
5. Autosomal Dominant Polycystic Kidney Disease Treatments & Medical Practices
6. Autosomal Dominant Polycystic Kidney Disease Marketed Therapies
6.1. Jynarque (tolvaptan): Otsuka Pharmaceuticals
7. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies
8. Key Cross Competition
8.1. Venglustat: Sanofi
8.2. Lixivaptan: Palladio Biosciences
8.3. Bardoxolone: Reata Pharmaceuticals
8.4. XRx-008: XORTX Therapeutics
8.5. RGLS4326: Regulus Therapeutics
9. Autosomal Dominant Polycystic Kidney Disease Market Size
10. 7MM Autosomal Dominant Polycystic Kidney Disease Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight<\/p>\n

Related reports:<\/strong><\/p>\n

Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n

Autosomal Dominant Polycystic Kidney Disease Pipeline Insight, 2020<\/a><\/strong> <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Anuj Rawat
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s ” Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475299","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475299"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475299\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}